These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 7518658

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC.
    J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
    [Abstract] [Full Text] [Related]

  • 3. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC.
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M, Mole L, Margolis D, Moss J, Dong H, Boyer E, Urdea M, Kolberg J, Eastman S.
    J Virol; 1995 Jun; 69(6):3510-6. PubMed ID: 7745698
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS.
    N Engl J Med; 1996 Oct 10; 335(15):1091-8. PubMed ID: 8813039
    [Abstract] [Full Text] [Related]

  • 13. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D, Bethel J, Wainberg MA, Weislow O, Schnittman S.
    J Infect Dis; 1998 Jun 10; 177(6):1730-3. PubMed ID: 9607859
    [Abstract] [Full Text] [Related]

  • 14. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E, Shirasaka T, Anderson BD, Chokekijchai S, Steinberg SM, Broder S, Yarchoan R, Mitsuya H.
    J Infect Dis; 1995 May 10; 171(5):1152-8. PubMed ID: 7751690
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
    Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, Larder BA.
    J Infect Dis; 1992 Jan 10; 165(1):105-10. PubMed ID: 1370174
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
    Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R.
    J Infect Dis; 1994 Apr 10; 169(4):722-9. PubMed ID: 8133086
    [Abstract] [Full Text] [Related]

  • 19. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 20. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
    Shepp DH, Ashraf A, Tang IT, Match ME, Millan C, Pergolizzi R.
    J Med Virol; 1996 Aug 20; 49(4):303-10. PubMed ID: 8877763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.